Refine by
Clinical Stage Articles & Analysis
811 news found
(Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. ...
ByKalaris
Synaptive’s integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers patient-centric information with automated efficiency across all stages of clinical interventions. About Unity Health Toronto Unity Health Toronto is a health care network and university -affiliated teaching and ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. ...
According to University of Arizona clinical professor of medicine and dream specialist, Rubin Naiman, PhD, the two key components of good sleep quality are non-REM and REM sleep. Unfortunately, sleep-tracking technology cannot measure rapid eye movement or REM sleep. This is the stage most closely associated with dreaming. As a result, we can’t always ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), is pleased to announce it was awarded a European Cannabinoid Patent, a novel Botanical and Tetrahydrocannabinol ("THC") ...
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth ...
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. ...
“Tris Pharma has a robust and expanding portfolio of clinically proven, best-in-class ADHD therapies,” said Englese. “I believe there is tremendous opportunity to help enhance the company’s commercial success by further expanding the availability of this growing portfolio, which offers a range of delivery and treatment options for both adults and children ...
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple ...
In these positions he was responsible for the Discovery, Pharmacology, Toxicology and DMPK (Drug Metabolism & Pharmacokinetics) activities in close collaboration with CMC (chemistry, manufacturing, control), Clinical Development as well as Regulatory Affairs ensuring smooth and successful project transition from research into early and late-stage ...
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. Araris stands to make an impact in the ADC space and I am honored to be a part of the ...
Used a celiac disease specific patient reported outcomes (PRO) instrument to demonstrate that latiglutenase also protects against adverse clinical effects of gluten consumption. First-time clinical-trial use of a gluten-immunogenic peptide (GIP) in urine assay to demonstrate ~95% elimination of gluten in the stomach (p < 0.0001) by latiglutenase. ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of ...
The company’s founding team includes highly experienced executives and internationally renowned experts with track records in developing retinal gene therapy programs from discovery to clinical stage: Dr. Caroline Man Xu (Co-founder and CEO), Prof. Dr. Martin Biel (Scientific Co-founder), and Prof. ...
The company is already advancing multiple novel biology, first-in-class programs towards the clinic and has more than a dozen similar pipeline opportunities emerging in early discovery. In his new role, Jeffrey Hatfield will continue to take an active role in the growth and maturation of Vividion towards a clinical-stage company, providing ...
ByBayer AG